{"pmid":32362487,"pmcid":"PMC7183953","title":"New Data and the Covid-19 Pandemic Mandate a Rethink of Antiplatelet Strategies in Patients With TIA or Minor Stroke Associated With Atherosclerotic Carotid Stenosis.","text":["New Data and the Covid-19 Pandemic Mandate a Rethink of Antiplatelet Strategies in Patients With TIA or Minor Stroke Associated With Atherosclerotic Carotid Stenosis.","Eur J Vasc Endovasc Surg","Naylor, A R","McCabe, D J H","32362487"],"journal":"Eur J Vasc Endovasc Surg","authors":["Naylor, A R","McCabe, D J H"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32362487","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.ejvs.2020.04.024","keywords":["antiplatelet therapy","carotid endarterectomy","covid-19"],"topics":["Prevention"],"weight":1,"_version_":1666138496080805888,"score":9.490897,"similar":[{"pmid":32448560,"title":"Preventing stroke in symptomatic carotid artery disease during the COVID-19 pandemic.","text":["Preventing stroke in symptomatic carotid artery disease during the COVID-19 pandemic.","J Vasc Surg","Hellegering, Joyce","van der Laan, Maarten J","Heide, Erik-Jan de","Uyttenboogaart, Maarten","Zeebregts, Clark J","Bokkers, Reinoud P H","32448560"],"journal":"J Vasc Surg","authors":["Hellegering, Joyce","van der Laan, Maarten J","Heide, Erik-Jan de","Uyttenboogaart, Maarten","Zeebregts, Clark J","Bokkers, Reinoud P H"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448560","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jvs.2020.04.476","topics":["Prevention"],"weight":1,"_version_":1667785214007443457,"score":69.1577},{"pmid":32474087,"title":"Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study.","text":["Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study.","Little is still known about the clinical features associated with the occurrence of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus disease 2019 (COVID-19). The aim of the present study was to describe the prevalence of pre-admission antithrombotic therapies in patients with COVID-19 and to investigate the potential association between antithrombotic therapy and ARDS, as disease clinical presentation, or in-hospital mortality. We enrolled 192 consecutive patients with laboratory-confirmed COVID-19 admitted to emergency department of five Italian hospitals. The study population was divided in two groups according to the evidence of ARDS at chest computed tomography at admission. Propensity score weighting adjusted regression analysis was performed to assess the risk ARDS at admission, and death during hospitalization, in patients treated or not with antiplatelet and anticoagulant agents. ARDS was reported in 73 cases (38%), who showed more likely hypertension compared to those without ARDS (57.8 % vs 49.6 %; P = 0.005). Thirty-five patients (18.5%) died during the hospitalization. Not survived COVID-19 patients showed a statistically significant increased age (77 +/- 8.31 vs 65.57 +/- 8.31; P = 0.001), hypertension (77.1% vs 53.5%; P = 0.018) and coronary artery disease prevalence (28.6% vs 10.2%; P = 0.009). Both unadjusted and adjusted regression analyses showed no difference in the risk of ARDS at admission, or death during hospitalization, between patients treated or not with antiplatelets or anticoagulants. Pre-admission antithrombotic therapy, both antiplatelet and anticoagulant, does not seem to show a protective effect in severe forms of COVID-19 with ARDS at presentation and rapidly evolving toward death.","Pharmacol Res","Russo, Vincenzo","Di Maio, Marco","Attena, Emilio","Silverio, Angelo","Scudiero, Fernando","Celentani, Dario","Lodigiani, Corrado","Di Micco, Pierpaolo","32474087"],"abstract":["Little is still known about the clinical features associated with the occurrence of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus disease 2019 (COVID-19). The aim of the present study was to describe the prevalence of pre-admission antithrombotic therapies in patients with COVID-19 and to investigate the potential association between antithrombotic therapy and ARDS, as disease clinical presentation, or in-hospital mortality. We enrolled 192 consecutive patients with laboratory-confirmed COVID-19 admitted to emergency department of five Italian hospitals. The study population was divided in two groups according to the evidence of ARDS at chest computed tomography at admission. Propensity score weighting adjusted regression analysis was performed to assess the risk ARDS at admission, and death during hospitalization, in patients treated or not with antiplatelet and anticoagulant agents. ARDS was reported in 73 cases (38%), who showed more likely hypertension compared to those without ARDS (57.8 % vs 49.6 %; P = 0.005). Thirty-five patients (18.5%) died during the hospitalization. Not survived COVID-19 patients showed a statistically significant increased age (77 +/- 8.31 vs 65.57 +/- 8.31; P = 0.001), hypertension (77.1% vs 53.5%; P = 0.018) and coronary artery disease prevalence (28.6% vs 10.2%; P = 0.009). Both unadjusted and adjusted regression analyses showed no difference in the risk of ARDS at admission, or death during hospitalization, between patients treated or not with antiplatelets or anticoagulants. Pre-admission antithrombotic therapy, both antiplatelet and anticoagulant, does not seem to show a protective effect in severe forms of COVID-19 with ARDS at presentation and rapidly evolving toward death."],"journal":"Pharmacol Res","authors":["Russo, Vincenzo","Di Maio, Marco","Attena, Emilio","Silverio, Angelo","Scudiero, Fernando","Celentani, Dario","Lodigiani, Corrado","Di Micco, Pierpaolo"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474087","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.phrs.2020.104965","keywords":["covid-19","sars-cov-2","acute distress respiratory syndrome","anticoagulant therapy","anticoagulation","antiplatelet therapy","atrial fibrillation","mortality"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1668341932670058496,"score":66.51331},{"pmid":32389423,"title":"Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection.","text":["Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection.","J Neuroradiol","Viguier, Alain","Delamarre, Louis","Duplantier, Julien","Olivot, Jean-Marc","Bonneville, Fabrice","32389423"],"journal":"J Neuroradiol","authors":["Viguier, Alain","Delamarre, Louis","Duplantier, Julien","Olivot, Jean-Marc","Bonneville, Fabrice"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389423","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.neurad.2020.04.003","topics":["Case Report"],"weight":1,"_version_":1666528580173037568,"score":55.624527},{"pmid":32427642,"title":"Getting to a New Normal: Mandating That Patients Wear Masks as Hospitals Fully Reopen during the Coronavirus Pandemic.","text":["Getting to a New Normal: Mandating That Patients Wear Masks as Hospitals Fully Reopen during the Coronavirus Pandemic.","Anesthesiology","Liu, Renyu","Fleisher, Lee A","32427642"],"journal":"Anesthesiology","authors":["Liu, Renyu","Fleisher, Lee A"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427642","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/ALN.0000000000003386","topics":["Prevention"],"weight":1,"_version_":1667252837926567936,"score":52.587475},{"pmid":32484159,"title":"Managing Severe Aortic Stenosis in the COVID-19 Era.","text":["Managing Severe Aortic Stenosis in the COVID-19 Era.","The novel coronavirus-19 (COVID-19) pandemic has created uncertainty in the management of patients with severe aortic stenosis (AS). This population experiences high mortality from delays in treatment of valve disease but is largely overlapping with the population of highest mortality from COVID-19. We present strategies for managing patients with severe AS in the COVID-era. We suggest transitions to virtual assessments and consultation, careful pruning and planning of necessary testing, as well as fewer and shorter hospital admissions. These strategies center on minimizing patient exposure to COVID-19 and expenditure of human and health-care resources without significant sacrifice to patient outcomes during this public health emergency. Areas of innovation to improve our care during this time include increased use of wearable and remote devices to assess patient performance and vital signs, devices for facile cardiac assessment, and widespread use of clinical protocols for expedient discharge with virtual physical therapy and cardiac rehabilitation options.","JACC Cardiovasc Interv","Tanguturi, Varsha K","Lindman, Brian R","Pibarot, Philippe","Passeri, Jonathan J","Kapadia, Samir","Mack, Michael J","Inglessis, Ignacio","Langer, Nathan B","Sundt, Thoralf M","Hung, Judy","Elmariah, Sammy","32484159"],"abstract":["The novel coronavirus-19 (COVID-19) pandemic has created uncertainty in the management of patients with severe aortic stenosis (AS). This population experiences high mortality from delays in treatment of valve disease but is largely overlapping with the population of highest mortality from COVID-19. We present strategies for managing patients with severe AS in the COVID-era. We suggest transitions to virtual assessments and consultation, careful pruning and planning of necessary testing, as well as fewer and shorter hospital admissions. These strategies center on minimizing patient exposure to COVID-19 and expenditure of human and health-care resources without significant sacrifice to patient outcomes during this public health emergency. Areas of innovation to improve our care during this time include increased use of wearable and remote devices to assess patient performance and vital signs, devices for facile cardiac assessment, and widespread use of clinical protocols for expedient discharge with virtual physical therapy and cardiac rehabilitation options."],"journal":"JACC Cardiovasc Interv","authors":["Tanguturi, Varsha K","Lindman, Brian R","Pibarot, Philippe","Passeri, Jonathan J","Kapadia, Samir","Mack, Michael J","Inglessis, Ignacio","Langer, Nathan B","Sundt, Thoralf M","Hung, Judy","Elmariah, Sammy"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32484159","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jcin.2020.05.045","topics":["Prevention"],"weight":1,"_version_":1668532114809683968,"score":52.425617}]}